Gland Pharma Limited
NSE: GLAND · Pharmaceuticals · sector
₹2,843.90NSE close 2026-10-26
Key numbers
Market cap₹46,913 cr
Price₹2,843.90
52w high / low₹3,171 / ₹1,574
P/E41.5xSector median 27.9x
P/B4.5xSector median 2.9x
Book value₹627.9
Dividend yield0.63%Sector median 0.48%
ROE11.6%Sector median 11.7%
ROCE15.2%Sector median 12.3%
OPM25.7%Sector median 14.0%
Debt / equity0.02xSector median 0.16x
EV/EBITDA25.4xSector median 18.6x
Interest cover61.7x
Current ratio4.68x
Sales growth 3y+21.1%Sector median +9.6%
Profit growth 3y+9.6%Sector median +13.3%
PEG4.35x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹3,359 cr vs borrowings ₹243 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 61.7x in the last 12 months.
- Promoter holding fell by 6.08 percentage points in a year, to 45.75% (2026-09-30).
- Operating cash flow was below net profit in 2 of the last 5 years (FY23, FY22).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 28% of net profit in the last 12 months.
- Dividend paid in 2 of the last 5 financial years.
- Price ₹2,843.90 on 2026-10-26: -10.3% from the 52-week high, +80.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹3,061.80 · low ₹1,392.80
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 |
| EBITDA | 297 | 360 | 348 | 368 | 314 | 411 | 513 | 489 |
| OPM % | 21.1% | 26.0% | 24.4% | 24.4% | 21.1% | 24.2% | 29.4% | 27.2% |
| Other income | 60 | 58 | 44 | 58 | 84 | 63 | 111 | 61 |
| Net profit | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 |
| EPS (₹) | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 | 19.23 |
| Revenue YoY | +5.8% | +22.5% | +22.3% | +19.6% | ||||
| Profit YoY | +12.3% | +27.7% | +96.6% | +47.1% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 4,401 | 3,625 | 5,665 | 5,616 | 6,431 | 6,725 |
| EBITDA | 1,510 | 968 | 1,333 | 1,269 | 1,605 | 1,727 |
| Net profit | 1,212 | 781 | 772 | 699 | 1,027 | 1,129 |
| EPS (₹) | 73.81 | 47.44 | 46.90 | 42.40 | 62.35 | 68.51 |
| Revenue growth | -17.6% | +56.3% | -0.9% | +14.5% | +17.6% | |
| Profit growth | -35.5% | -1.1% | -9.6% | +47.1% | +46.5% | |
| Dividend / share (₹) | – | – | – | 20.00 | 18.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +21.1% | +13.2% | +17.6% |
| Net profit | +9.6% | +0.6% | +46.5% |
| EPS | +9.5% | -0.2% | – |
| Share price | – | +32.4% (2y) | +52.7% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 7,959 | 8,724 | 9,151 | 10,358 |
| Borrowings | – | 4 | 320 | 269 | 243 |
| Cash & equivalents | – | 3,771 | 1,839 | 2,556 | 3,359 |
| Total assets | – | 8,778 | 10,661 | 11,225 | 12,511 |
| Fixed assets | – | 1,558 | 3,541 | 3,751 | 4,052 |
| Capital work in progress | – | 177 | 238 | 151 | 342 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 871 | 1,559 | 1,517 | 1,891 |
| Inventory | – | 1,945 | 1,655 | 1,685 | 1,744 |
| Payables | – | 587 | 863 | 820 | 834 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 791 | 364 | 997 | 915 | 1,031 |
| Cash from investing | -1,003 | 1,208 | -1,757 | 1,705 | 138 |
| Cash from financing | 35 | 15 | -799 | -433 | -417 |
| Capex | 522 | 223 | 398 | 394 | 494 |
| Free cash flow | 269 | 141 | 599 | 521 | 537 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 9.8% | 8.9% | 7.6% | 9.9% |
| ROCE % | – | 13.3% | 12.8% | 11.7% | 14.1% |
| Debtor days | – | 88 | 100 | 99 | 107 |
| Inventory days | – | 421 | 278 | 294 | 284 |
| Payable days | – | 127 | 145 | 143 | 136 |
| Cash conversion cycle (days) | – | 382 | 233 | 250 | 255 |
| Working capital days | – | 621 | 274 | 339 | 336 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 45.75% |
| FIIs | 10.36% |
| DIIs | 33.21% |
| of which Mutual funds | 29.52% |
| of which Insurance | 2.43% |
| Government | 0.01% |
| Public (non-institutions) | 10.66% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.77% | 45.75% |
| Promoter group | % |
|---|---|
| Fosun Pharma Industrial Pte. Ltd | 45.75% |
| Ample Up Limited | 0.00% |
| Fosun Industrial Co Limited | 0.00% |
| Lustrous Star Limited | 0.00% |
| Regal Gesture Limited | 0.00% |
| Public holders above 1% | % |
|---|---|
| Hdfc Mutual Fund - Hdfc Mid-Cap Fund | 5.60% |
| Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund | 4.87% |
| Sbi Large & Midcap Fund | 3.20% |
| Mirae Asset Large & Midcap Fund | 2.92% |
| Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund | 2.51% |
| Kotak Midcap Fund | 2.42% |
| Dsp Small Cap Fund | 1.57% |
| Hdfc Life Insurance Company Limited | 1.51% |
| Icici Prudential India Opportunities Fund | 1.41% |
| Government Pension Fund Global | 1.32% |
| Uti-Flexi Cap Fund | 1.23% |
| Canara Robeco Mutual Fund A/C Canara Robeco Small Cap Fund | 1.06% |
1,25,667 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| GLAND | ₹46,913 cr | 41.5x | 4.5x | 11.6% | 15.2% | 25.7% | +21.1% | 0.63% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-08-11 | Dividend | Dividend - Rs 20 Per Sh |
| 2025-08-14 | Dividend | Dividend - Rs 18 Per Share |
| 2024-08-16 | Dividend | Annual General Meeting/Dividend - Rs 20 Per Share |
| 2021-08-06 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Pharmaceuticals.: Pharmaceutical research and development, manufacturing, and marketing of complex injectables.
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | GLAND |
| BSE code | 543245 |
| ISIN | INE068V01023 |
| Face value | ₹1.0 |
| Incorporated | 1978-03-20 |
| Website | www.glandpharma.com |
| Plants (India / abroad) | 6 / 4 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.